PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.

Roche dumps another partnered asset.

Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

Bristol buys into the frenzy, and VEGF bispecific value inflation continues.

Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.